Diabetes pill may reverse early heart damage, small study suggests

NCT ID NCT07186153

Not yet recruiting Disease control Sponsor: Assiut University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at whether common diabetes drugs called SGLT2 inhibitors (like empagliflozin and dapagliflozin) can improve the structure and function of the heart's left atrium in people with type 2 diabetes. Researchers will use advanced ultrasound to measure heart changes in 100 adults aged 40-75 before and after 6 months of treatment. The goal is to see if these drugs can reverse early signs of heart strain caused by diabetes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SGLT2 inhibitors (empagliflozin, dapagliflozin)
What this could lead to: If successful, this could show that SGLT2 drugs help reverse early heart damage in people with diabetes, potentially reducing future heart failure risk.
What could go wrong: This is a small, early-phase study with only 100 participants and no control group. Results may not apply to all diabetes patients, and the heart changes measured may not translate to fewer heart problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SGLT 2 INHIBITORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SGLT 2 INHIBITORS

More trials for these conditions

Other studies related to the condition(s) this trial covers.